Roots Analysis
AUGUST 15, 2023
In addition to the healthcare industry, other industries, such as food industry, cosmetics industry and enzyme synthesis industry, are also benefiting from the cell free manufacturing process.
FDA Law Blog
JANUARY 12, 2025
Since that time, it was formalized in FDA regulations (21 CFR 314 Subpart H) in 1992, codified in the Food, Drug, & Cosmetic Act by FDAMA (21 USC 356(c)) in 1997, revised by FDASIA in 2012, and described in guidance, most importantly, in the 2014 Expedited Programs for Serious Conditions Drugs and Biologics (2014 Guidance).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pfizer
AUGUST 15, 2022
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. IMPORTANT SAFETY INFORMATION.
Roots Analysis
SEPTEMBER 9, 2024
Protein expression is a potent technology in the field of synthetic biology, that is utilized for the high-throughput production of proteins as well as enzymes and oligonucleotides (DNA / RNA). This process initially involves transcription of DNA to messenger RNA (mRNA). The mRNA is then translated into to form functional proteins.
The Pharma Data
DECEMBER 18, 2020
The Moderna COVID-19 Vaccine contains messenger RNA (mRNA), which is genetic material. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products. SOURCE U.S.
Pfizer
DECEMBER 13, 2022
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. IMPORTANT SAFETY INFORMATION .
Pfizer
DECEMBER 20, 2022
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. IMPORTANT SAFETY INFORMATION.
Expert insights. Personalized for you.
52 
Let's personalize your content